Inhibition of human ether-a-go-go-related gene potassium channels by α1-adrenoceptor antagonists prazosin, doxazosin, and terazosin

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 369, Issue 5, 2004, Pages 462-472

  Thomas, Dierk ^a   Wimmer, Anna Britt ^a   Wu, Kezhong ^a   Hammerling, Bettina C ^a   Ficker, Eckhard K ^b   Kuryshev, Yuri A ^b   Kiehn, Johann ^a   Katus, Hugo A ^a   Schoels, Wolfgang ^a   Karle, Christoph A ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

Apoptosis; Arrhythmia; Doxazosin; HERG; Long QT syndrome; Potassium channel; Prazosin; Terazosin

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; DOXAZOSIN; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; PRAZOSIN; QUINAZOLINE; TERAZOSIN;

ADENOCARCINOMA; ALPHA CHAIN; APOPTOSIS; ARTICLE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; EMBRYO; HEART; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; IC 50; LONG QT SYNDROME; MEMBRANE POTENTIAL; OOCYTE; PROSTATE HYPERTROPHY; TUMOR CELL; XENOPUS;

ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; APOPTOSIS; CELLS, CULTURED; DOXAZOSIN; ELECTRIC STIMULATION; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNELS, VOLTAGE-GATED; PRAZOSIN; XENOPUS;

EID: 2442702680     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-004-0931-8     Document Type: Article

References (50)

1. Abbott GW, Sesti F, Splawski I, Buck ME, Lehmann MH, Timothy KW, Keating MT, Goldstein SA (1999) MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 97:175-187
2. Akduman B, Crawford ED (2001) Terazosin, doxazosin, and prazosin: current clinical experience. Urology 58:49-54
3. ALLHAT Research Group (2000) Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 283:1967-1975
4. Benning CM, Kryprianou N (2002) Quinazoline-derived α1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an α1-adrenoceptor- independent action. Cancer Res 62:597-602
5. Bian J, Cui J, McDonald TV (2001) HERG K(+) channel activity is regulated by changes in phosphatidyl inositol 4,5-bisphosphate. Circ Res 89:1168-1176
6. Bianchi L, Wible B, Arcangeli A, Tagliatatela M, Morra F, Castaldo P, Crociati O, Rosato B, Faravelli L, Olivotto M, Wanke E (1998) HERG encodes a K+ current highly conserved in tumors of different histogenesis: a selective advantage for cancer cells? Cancer Res 58:815-822
7. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P, Poyser RH, Ruffalo RR (1996) Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276:637-646
8. Chaignon M, Le Roux E, Aubert P, Lucsko M, Safar M, Flouvat B, Guedon J (1981) Clinical pharmacology of prazosin in hypertensive patients with chronic renal failure. J Cardiovasc Pharmacol 3:151-160
9. Cherubini A, Taddei GL, Crociani O, Paglierani M, Buccoliero AM, Fontana L, Noci I, Borri P, Borrani E, Giachi M, Becchetti A, Rosati B, Wanke E, Olivotto M, Arcangeli A (2000) HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium. Br J Cancer 83:1722-1729
10. Chouabe C, Drici MD, Romey G, Barhanin J, Lazdunski M (1998) HERG and KvLQT1/IsK, the cardiac K+ channels involved in long QT syndromes, are targets for calcium channel blockers. Mol Pharmacol 54:695-703
11. Crociani O, Guasti L, Balzi M, Becchetti A, Wanke E, Olivotto M, Wymore RS, Arcangeli A (2003) Cell-cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells. J Biol Chem 278:2947-2955
12. Elliott HL, Meredith PA, Reid JL (1987) Pharmacokinetic overview of doxazosin. Am J Cardiol 59:78G-81G
13. Fawzy A, Vashi V, Chung M, Dias N, Gaffney M (1999) Clinical correlation of maximal urinary flow rate and plasma doxazosin concentrations in the treatment of benign prostatic hyperplasia. Multicenter Study Group. Urology 53:329-335
14. Gonzalez-Juanatey JR, Iglesias MJ, Alcaide C, Pinero R, Lago F (2003) Doxazosin induces apoptosis in cardiomyocytes cultured in vitro by a mechanism that is independent of α1-adrenergic blockade. Circulation 107:127-131
15. Grimm RH Jr (1989) Alpha 1-antagonists in the treatment of hypertension. Hypertension 13:1131-1136
16. Hamill OP, Marty A, Neher E, Sakman B, Sigworth FJ (1981) Improved patch clamp techniques for high resolution current recording from cells and cell free membrane patches. Pflugers Arch Eur J Physiol 391:58-100
17. Jaillon P (1980) Clinical pharmacokinetics of prazosin. Clin Pharmacokinet 5:365-376
18. Jiang M, Dun W, Fan JS, Tseng GN (1999) Use-dependent 'agonist' effect of azimilide on the HERG channel. J Pharmacol Exp Ther 291:1324-1336
19. Kang PM, Izumo S (2000) Apoptosis and heart failure: a critical review of the literature. Circ Res 99:6252-6256
20. Karle CA, Kreye VAW, Thomas D, Rockl K, Kathofer S, Zhang W, Kiehn J (2001) Antiarrhythmic drug carvedilol inhibits HERG potassium channels. Cardiovasc Res 49:361-370
21. Kiehn J, Thomas D, Karle CA, Schöls W, Kübler W (1999) Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn-Schmiedebergs Arch Pharmacol 359:212-219
22. Kyprianou N (2003) Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance. J Urol 169: 1520-1525
23. Kyprianou N, Benning CM (2000) Suppression of human prostate cancer cell growth by α1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res 60:4550-4555
24. Mitcheson JS (2003) Drug binding to HERG channels: evidence for a 'non-aromatic' binding site for fluvoxamine. Br J Pharmacol 139:883-884
25. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000a) A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97:12329-12333
26. Mitcheson JS, Chen J, Sanguinetti MC (2000b) Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 115:229-240
27. Napolitano C, Priori S, Schwartz P (1994) Torsade de pointes: mechanism and management. Drugs 47:51-65
28. National Institutes of Health (1996) NIH publication no. 85-23, revised edn. NIH, Bethesda, MD
29. Patterson SE (1985) Terazosin kinetics after oral and intravenous doses. Clin Pharmacol Ther 38:423-427
30. Pitterman AB, Rollins DE, Shen DD, Hurwitz A, Hassanein KM (1981) Alpha adrenoceptor blockade with oral prazosin. Clin Pharmacol Ther 29:143-148
31. Pool JL (1996) Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract 50:154-163
32. kr potassium channel. Cell 81: 299-307
33. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathöfer S, Thomas D, Weretka S, Peth S, Kreye VAW, Schoels W, Katus HA, Kiehn J, Karle CA (2003) Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn-Schmiedebergs Arch Pharmacol 368:404-414
34. Shionoiri H, Yasuda G, Yoshimura H, Umemura S, Miyajima E, Miyakawa T, Takagi N, Kaneko Y (1987) Antihypertensive effects and pharmacokinetics of single and consecutive administration of doxazosin in patients with mild to moderate essential hypertension. J Cardiovasc Pharmacol 10:90-95
35. Smith GAM, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FWL, Schlichter LC (2002) Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem 277: 18528-18534
36. Sonders RC (1986) Pharmacokinetics of terazosin. Am J Med 80:20-24
37. Taguchi K, Schafers RF, Michel MC (1998) Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. Br J Clin Pharmacol 45:49-55
38. Thomas D, Zhang W, Karle CA, Kathofer S, Schols W, Kiehn J (1999) Deletion of protein kinase A phosphorylation sites in the HERG potassium channel inhibits activation shift by protein kinase A. J Biol Chem 274:27457-27462
39. Thomas D, Wendt-Nordahl G, Röckl K, Ficker E, Brown AM, Kiehn J (2001) High-affinity blockade of HERG human cardiac potassium channels by the novel antiarrhythmic drug BRL-32872. J Pharmacol Exp Ther 297:753-761
40. Thomas D, Gut B, Wendt-Nordahl G, Kiehn J (2002) The antidepressant drug fluoxetine is an inhibitor of human ether-a-go-go-related gene (HERG) potassium channels. J Pharmacol Exp Ther 300:543-548
41. Thomas D, Kiehn J, Katus HA, Karle CA (2003a) Defective protein trafficking in hERG-associated hereditary long QT syndrome (LQT2): molecular mechanisms and restoration of intracellular protein processing. Cardiovasc Res 60:239-245
42. Thomas D, Wu K, Kathöfer S, Katus HA, Schoels W, Kiehn J, Karle CA (2003b) The antipsychotic drug chlorpromazine inhibits HERG potassium channels. Br J Pharmacol 139:567-574
43. Thomas D, Gut B, Karsai S, Wimmer AB, Wu K, Wendt-Nordahl G, Zhang W, Kathofer S, Schoels W, Katus HA, Kiehn J, Karle CA (2003c) Inhibition of cloned HERG potassium channels by the antiestrogen tamoxifen. Naunyn-Schmiedebergs Arch Pharmacol 368:41-48
44. Thomas D, Zhang W, Wu K, Wimmer AB, Gut B, Wendt-Nordahl G, Kathofer S, Kreye VAW, Katus HA, Schoels W, Kiehn J, Karle CA (2003d) Regulation of HERG potassium channel activation by protein kinase C independent of direct phosphorylation of the channel protein. Cardiovasc Res 59:14-26
45. Viskin S (1999) Long QT syndromes and torsade de pointes. Lancet 354:1625-1633
46. Wang H, Zhang Y, Cao L, Han H, Wang J, Yang B, Nattell S, Wang Z (2002) HERG K+ channel, a regulator of tumor cell apoptosis and proliferation. Cancer Res 62:4843-4848
47. Warmke JW, Ganetzky B (1994) A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 91:3438-3442
48. Weerapura M, Nattel S, Chartier D, Caballero R, Hebert TE (2002) A comparison of currents carried by HERG, with and without coexpression of MiRP1, and the native rapid delayed rectifier current. Is MiRP1 the missing link? J Physiol 540:15-27
49. Wonderlin WF, Strobel JS (1996) Potassium channels, proliferation and G1 progression. J Membr Biol 154:91-107
50. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT (1999) Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84:989-998